ValuEngine upgraded shares of Oncolytics Biotech (OTCMKTS:ONCYF) from a strong sell rating to a sell rating in a research report sent to investors on Friday morning.
Shares of Oncolytics Biotech (ONCYF) opened at $0.68 on Friday. The stock has a market capitalization of $95.81, a price-to-earnings ratio of -7.51 and a beta of 1.48. Oncolytics Biotech has a 1-year low of $0.19 and a 1-year high of $0.85.
TRADEMARK VIOLATION WARNING: “Oncolytics Biotech (ONCYF) Upgraded by ValuEngine to Sell” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://www.com-unik.info/2018/01/08/oncolytics-biotech-oncyf-upgraded-by-valuengine-to-sell.html.
Oncolytics Biotech Inc is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company’s clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials.
To view ValuEngine’s full report, visit ValuEngine’s official website.
What are top analysts saying about Oncolytics Biotech? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Oncolytics Biotech and related companies.